FDA Adverse Event Injury Summary report: N

AMPLATZER PFO OCCLUDER

MDR report key: 6257442 · Received January 17, 2017

Report

Report Number
2135147-2017-00008
Event Type
Injury
Date Received
January 17, 2017
Date of Event
December 13, 2016
Report Date
December 20, 2016
Manufacturer
AGA MEDICAL CORPORATION
Product Code
MLV
PMA / PMN Number
P120021
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
UK
Reporter Occupation
PHYSICIAN

Narratives

Additional Manufacturer Narrative · 1

(B)(4). THE RESULTS OF THE INVESTIGATION ARE INCONCLUSIVE SINCE THE DEVICE WAS NOT RETURNED FOR ANALYSIS. OUR INVESTIGATION WAS LIMITED TO THE REVIEW OF THE DEVICE HISTORY RECORD, WHICH SHOWED THAT EACH MANUFACTURING AND INSPECTION OPERATION WAS PERFORMED AND INDICATED COMPLETE IN ACCORDANCE WITH SJM SPECIFICATIONS AND PROCEDURES. BASED ON THE INFORMATION RECEIVED, THE CAUSE OF THE REPORTED INCIDENT COULD NOT BE CONCLUSIVELY DETERMINED.

Description of Event or Problem · 1

ON (B)(6) 2016, THE AMPLATZER PFO OCCLUDER (PFO) WAS IMPLANTED IN THE PATIENT'S LARGE PFO WITH AN ANEURYSMAL SEPTUM. THE PFO WAS POSITIONED AND SEVERAL STABILITY TESTS WERE PERFORMED BEFORE RELEASE. THE PATIENT WAS DISCHARGED TO HOME ON THE SAME DAY. HEMOSTASIS HAD BEEN ACHIEVED; HOWEVER, AFTER LEAVING THE HOSPITAL THE PATIENT TRAVELLED 2-3 HOURS HOME. THAT EVENING THE PATIENT WENT TO ANOTHER HOSPITAL AND WAS TREATED FOR A GI BLEED. THERE WAS CONCERN BY THE CONSULTANTS THAT THE PFO DEVICE EMBOLIZED SECONDARY TO A VALSALVA MANEUVER AT THIS TIME. ON (B)(6) 2016, THE PATIENT PRESENTED FOR A FOLLOW-UP TOE POST PFO CLOSURE. THE PFO WAS DIFFICULT TO IMAGE, BUT A LEFT TO RIGHT STUNT WAS REVEALED. A CHEST X-RAY CONFIRMED THE PFO HAD EMBOLIZED IN THE PATIENT'S PA. THE PATIENT WAS PLACED ON APIXOBAHN. ON (B)(6) 2016, SURGERY WAS PERFORMED TO REMOVE THE PFO AND CLOSE THE PATIENT'S PFO. THE PATIENT WAS REPORTED TO BE IN STABLE CONDITION.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
40998 AMPLATZER PFO OCCLUDER CARDIAC OCCLUSION DEVICE MLV AGA MEDICAL CORPORATION 9-PFO-025 5148783

Patients

Seq Age Sex Outcome Treatment
1 44 YR Hospitalization| R